A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior

Jermaine D. Jones, Shanna Babalonis, Ronald Marcus, Bradley Vince, Debra Kelsh, Michelle R. Lofwall, Heather Fraser, Blake Paterson, Suky Martinez, Diana M. Martinez, Edward V. Nunes, Sharon L. Walsh, Sandra D. Comer

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Fingerprint

Dive into the research topics of 'A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience